Illumina has recently advanced its plan to divest its cancer-diagnostics unit, a move intended to ease regulatory pressure and sharpen its focus on core DNA sequencing and microarray technologies.

Canaccord Genuity analyst Kyle Mikson CFA has maintained their neutral stance on ILMN stock, giving a Hold rating today. Geoff Meacham has given his Hold rating due to a combination of factors ...

RBC Capital analyst Conor McNamara maintained a Buy rating on Illumina (ILMN – Research Report) yesterday and set a price target of $242.00. The company’s shares closed last Friday at $104.38.

The base and pessimistic DCF models implemented in this article suggest that Illumina is undervalued. Illumina expects to reach a growth rate in its revenues of 6%-9% CAGR by 2027. The DNA sequencing ...

Not all profitable companies are built to last - some rely on outdated models or unsustainable advantages. Just because a ...

Wall Street analysts forecast that Illumina (ILMN) will report quarterly earnings of $0.87 per share in its upcoming release, pointing to a year-over-year increase of 163.6%. It is anticipated that ...

In the last three months, 11 analysts have published ratings on Illumina (NASDAQ:ILMN), offering a diverse range of perspectives from bullish to bearish. The table below offers a condensed view of ...